WHAT IS CLAIMED IS:

1. A Wnt-binding agent comprising:
(a) a first polypeptide ~~comprising~~ consisting of SEQ ID NO:39~~; SEQ ID NO:32; SEQ ID NO:33; SEQ ID NO:34; SEQ ID NO:35; SEQ ID NO:36; SEQ ID NO:37; SEQ ID NO:38; SEQ ID NO:40; or SEQ ID NO:41~~; and
(b) a second polypeptide comprising SEQ ID NO:43 ~~or SEQ ID NO:42~~;
wherein the first polypeptide is directly linked to the second polypeptide.

~~2. The Wnt-binding agent of claim 1, wherein the first polypeptide comprises SEQ ID NO:39~~.

~~3. The Wnt-binding agent of claim 1, wherein the first polypeptide consists of SEQ ID NO:39; and wherein the second polypeptide consists of SEQ ID NO:43 or SEQ ID NO:42~~.

4 2. The Wnt-binding agent of claim 1, ~~wherein the first polypeptide consists of SEQ ID NO:39; and~~ wherein the second polypeptide consists of SEQ ID NO:43.

~~5~~ 3. A Wnt-binding agent comprising:
(a) a first polypeptide comprising amino acids X to Y of SEQ ID NO:30; and
(b) a second polypeptide comprising ~~amino acids A to B of~~ SEQ ID NO:43;
wherein the first polypeptide is directly linked to the second polypeptide; and
wherein X = amino acid 25, 26, 27, or 28; and~~, 29, 30, or 31~~
Y = amino acid ~~156, 157,~~ 158, 159, 160, 161, 162, 163, or 164
~~A = amino acid 1, 2, 3, 4, or 5~~
~~B = amino acid 231 or 232~~.

~~6~~ 4. A Wnt-binding agent comprising ~~an~~ the amino acid sequence ~~selected from the group consisting~~ of~~:~~ SEQ ID NO:53~~, SEQ ID NO:50, SEQ ID NO:48, and SEQ ID NO:46~~.

~~7~~ 5. ~~The~~ A Wnt-binding agent consisting of ~~claim 6, wherein the amino acid sequence is~~ SEQ ID NO:53.

~~8. The Wnt-binding agent of claim 6, wherein the amino acid sequence is SEQ ID NO:50.~~

~~9~~ 6. A polypeptide comprising the Wnt-binding agent of any one of claims 1 to ~~8~~ 5, and further comprising ~~an~~ the amino acid sequence ~~selected from the group consisting~~ of~~:~~ SEQ ID

NO:72~~, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:73, and SEQ ID NO:74~~.

~~10~~ 7. A polypeptide ~~comprising~~ consisting of SEQ ID NO:72 and SEQ ID NO:53.

~~11~~ 8. A cell producing the Wnt-binding agent of any one of claims 1 to ~~8~~ 5.

~~12~~ 9. A cell comprising the polypeptide of claim ~~9~~ 6 or claim ~~10~~ 7.

~~13~~ 10. A composition comprising the Wnt-binding agent of any one of claims 1 to ~~8~~ 5, wherein at least about 80% of the Wnt-binding agent has an N-terminal amino acid sequence of ASA.

~~14~~ 11. A pharmaceutical composition comprising the Wnt-binding agent of any one of claims 1 to ~~8~~ 5, and a pharmaceutically acceptable carrier.

~~15~~ 12. A polynucleotide comprising a polynucleotide that encodes the Wnt-binding agent of any one of claims 1 to ~~8~~ 5.

~~16~~ 13. A polynucleotide comprising a polynucleotide that encodes the polypeptide of claim ~~9~~ 6 or claim ~~10~~ 7.

~~17~~ 14. A cell comprising the polynucleotide of claim ~~15~~ 12 or claim ~~16~~ 13.

~~18~~ 15. Use of the Wnt-binding agent of any one of claims 1 to ~~8~~ 5 in the manufacture of a medicament for the treatment of cancer.

~~19~~ 16. Use of the Wnt-binding agent of any one of claims 1 to ~~8~~ 5 in the manufacture of a medicament for treatment of a disease associated with Wnt signaling activation.

~~20~~ 17. The use of the Wnt-binding agent of claim ~~18~~ 15 or claim ~~19~~ 16, wherein the treatment comprises a second therapeutic agent.

~~21~~ 18. A method of producing the Wnt-binding agent of any one of claims 1 to ~~8~~ 5, wherein at least about 80% of the Wnt-binding agent has an N-terminal amino acid sequence of ASA, the method comprising using a signal sequence ~~selected from the group consisting~~ of~~:~~ SEQ ID NO:72~~, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:73, and SEQ ID NO:74~~ for production of the Wnt-binding agent.

~~22~~ 19. A polypeptide comprising:
(a) a signal sequence ~~selected from the group consisting~~ of~~:~~ SEQ ID NO:72~~, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:73, and SEQ ID NO:74~~;
(b) a Fri domain of human FZD8; and
(c) a human Fc region.

~~23~~ 20. A polynucleotide comprising a polynucleotide that encodes the polypeptide of claim ~~22~~ 19.

~~24~~ 21. A cell comprising the polynucleotide of claim ~~23~~ 20.

~~25~~ 22. A cell comprising the polypeptide of claim ~~22~~ 19.

~~26~~ 23. A method of producing a soluble Wnt-binding agent which comprises a Fri domain of human FZD8 in a cell, wherein at least about 80% of the Wnt-binding agent has an N-terminal amino acid sequence of ASA, the method comprising using a signal sequence ~~selected from the group consisting~~ of~~:~~ SEQ ID NO:72~~, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:73, and SEQ ID NO:74~~ for production of the Wnt-binding agent.

~~27~~ 24. A soluble Wnt-binding agent produced by the method of claim ~~26~~ 23.

~~28~~ 25. A composition comprising a soluble Wnt-binding agent which comprises a Fri domain of human FZD8, wherein at least about 80% of the Wnt-binding agent has an N-terminal sequence of ASA.